Displaying drugs 7676 - 7700 of 8179 in total
Rilematovir
Rilematovir is under investigation in clinical trial NCT04056611 (Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)).
Investigational
Matched Description: … Rilematovir is under investigation in clinical trial NCT04056611 (Effects of JNJ-53718678 in Adult and …
Miricorilant
Miricorilant is under investigation in clinical trial NCT03818256 (Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia and Recent Weight Gain While Taking Antipsychotic Medications (GRATITUDE)).
Investigational
Matched Description: … investigation in clinical trial NCT03818256 (Study Evaluating the Safety, Efficacy, and Pharmacokinetics of …
Exbivirumab
Exbivirumab is an investigational monoclonal antibody. It is one of the active ingredients in HepeX-B, a drug product containing two human monoclonal antibodies to the hepatitis B virus (HBV) surface antigen.
Investigational
Matched Description: … It is one of the active ingredients in HepeX-B, a drug product containing two human monoclonal antibodies …
Libivirumab
Libivirumab is an investigational monoclonal antibody. It is one of the active ingredients in HepeX-B, a drug product containing two human monoclonal antibodies to the hepatitis B virus (HBV) surface antigen.
Investigational
Matched Description: … It is one of the active ingredients in HepeX-B, a drug product containing two human monoclonal antibodies …
AMP-101
AMP-101 is a gene therapy comprising an adeno-associated virus type 9 (AAV9) vector encoding the human Dok-7 protein. It is under investigation for the treatment of Dok-7-associated myasthenia.
Investigational
Matched Description: … It is under investigation for the treatment of Dok-7-associated myasthenia. …
Dental Mesenchymal Pulp Stem Cells
Dental pulp is a soft, connective tissue present in the dental crown of both third molar and first premolar teeth. Dental pulp stem cells (DPSCs) exhibit fibro-blast like plasticity and adherent properties. They are harvested through surgical extraction of wisdom teeth from adults; this procedure is favoured as it is...
Investigational
Matched Description: … Dental pulp is a soft, connective tissue present in the dental crown of both third molar and first premolar ... They are harvested through surgical extraction of wisdom teeth from adults; this procedure is favoured ... as it is non-invasive, easily accessible, and allows for an alternate use of teeth that are usually …
UB-612
The UB-612 COVID-19 vaccine was developed by United Biomedical Inc Asia in Taipei as the first COVID-19 “multi-tope” protein-peptide vaccine made up of eight rationally designed components . The vaccine incorporates a strong S1-RBD component linked to a single chain fragment region (sFC) of a human IgG1, which facilitates cell...
Investigational
Matched Description: … United Biomedical Inc Asia in Taipei as the first COVID-19 “multi-tope” protein-peptide vaccine made up of ... The vaccine incorporates a strong S1-RBD component linked to a single chain fragment region (sFC) of ... a human IgG1, which facilitates cell attachment and acts as the principal neutralizing domain of the …
XL999
XL999 has the potential to provide benefit to patients with lung cancer and acute myelogenous leukemia. XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth promoting and angiogenic properties, including FGFR 1/3, PDGFRα/β, VEGFR2/KDR, KIT, and FLT3. XL999 also inhibits FLT4 and...
Investigational
Matched Description: … XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth ... growth — both directly by a novel effect on tumor cell proliferation and indirectly through inhibition of …
NUC B1000
NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid delivery system. eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to...
Investigational
Matched Description: … NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct ... On January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its …
AV-COVID-19
AV-COVID-19 is a vaccine composed of autologous dendritic cells loaded with SARS-CoV-2 antigens and with or without Granulocyte-macrophage colony-stimulating factor (GM-CSF).
The vaccine is created from the receiving patients’ isolated peripheral blood monocytes. The monocytes are then differentiated in vitro into dendritic cells with IL-4 and GM-CSF, incubated with SARS-CoV-2...
Investigational
Matched Description: … AV-COVID-19 is a vaccine composed of autologous dendritic cells loaded with SARS-CoV-2 antigens and with ... As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252 …
YSIL6
YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid arthritis and psoriasis. The molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and macrophages, and by inhibiting T-cell proliferation and migration.
Investigational
Matched Description: … YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid …
CR002
CR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation. This is a novel therapeutic approach to treat kidney inflammation.
Investigational
Matched Description: … CR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived …
Ranirestat
Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels. It has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy.
Investigational
Matched Description: … It has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy …
PRO-542
PRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells. PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates.
Investigational
Matched Description: … PRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from …
CCR5 mAb
CCR5 mAb is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor CCR5, which is known to be a key facilitator of infection with human immunodeficiency virus (HIV-1). It was generated by HGS using the Abgenix XenoMouse technology.
Investigational
Matched Description: … specifically recognizes and binds the chemokine receptor CCR5, which is known to be a key facilitator of …
Zastumotide
Zastumotide is a recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (MAGE-A3 ASCI) also known as astuprotimut-R. It is under investigation in clinical trial NCT00257738 (0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck).
Investigational
Matched Description: … investigation in clinical trial NCT00257738 (0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of …
Pateclizumab
Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis).
Investigational
Matched Description: … Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of …
Efinopegdutide
Efinopegdutide is under investigation in clinical trial NCT03606057 (A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)).
Investigational
Matched Description: … Efinopegdutide is under investigation in clinical trial NCT03606057 (A Study to Investigate the Effect of …
GX-19 Vaccine
The GX-19 vaccine is a DNA vaccine created by Genexine, Inc. Company in Gyeonggi, Korea . As of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels for safety and efficacy[A219758,L16488].
Investigational
Matched Description: … As of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels …
Gavocabtagene autoleucel
Gavocabtagene autoleucel is a novel cell therapy consisting of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex.
Investigational
Matched Description: … Gavocabtagene autoleucel is a novel cell therapy consisting of autologous genetically engineered T cells …
D2C7 immunotoxin
D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the Pseudomonas exotoxin, PE38-KDEL. D2C7-IT is under investigation in clinical trial NCT04160494 (D2C7-IT With Atezolizumab for Recurrent Gliomas).
Investigational
Matched Description: … dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of …
Livmoniplimab
Livmoniplimab is under investigation in clinical trial NCT06109272 (A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)).
Investigational
Matched Description: … clinical trial NCT06109272 (A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of …
Tezosentan
Tezosentan is an intravenous endothelin receptor A/B antagonist. Tezosentan was initially developed for vasodilation in patients with acute heart failure but studies have shown that it does not assist in the treatment of dyspnea or prevent cardiovascular events.
Investigational
Matched Description: … in patients with acute heart failure but studies have shown that it does not assist in the treatment of …
Dacetuzumab
Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, Leukemia, Lymphocytic, Chronic, and Lymphoma, Large B-Cell, Diffuse. It is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells.
Investigational
Matched Description: … Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, …
GI-101
GI-101 is a bi-specific fragment crystallizable region (Fc) fusion protein containing a cluster of differentiation 80 ectodomain as an N-terminal moiety and interleukin-2 variant as a C-terminal moiety conjugated with human immunoglobulin G4 Fc.
Investigational
Matched Description: … GI-101 is a bi-specific fragment crystallizable region (Fc) fusion protein containing a cluster of differentiation …
Displaying drugs 7676 - 7700 of 8179 in total